Alnylam Pharmaceuticals, Inc. (LON:0HD2)
291.48
+6.75 (2.37%)
At close: May 27, 2025
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $594.19M USD in the quarter ending March 31, 2025, with 20.20% growth. This brings the company's revenue in the last twelve months to $2.35B, up 17.21% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.
Revenue (ttm)
$2.35B
Revenue Growth
+17.21%
P/S Ratio
16.26
Revenue / Employee
$1.05M
Employees
2,230
Market Cap
29.54B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Alnylam Pharmaceuticals News
- 17 days ago - Alnylam Issues 2024 Corporate Responsibility Report - Business Wire
- 20 days ago - Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - Seeking Alpha
- 20 days ago - AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
- 25 days ago - Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
- 4 weeks ago - $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga
- 4 weeks ago - Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference - Business Wire
- 5 weeks ago - Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
- 5 weeks ago - Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga